Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Graefe's Archive for Clinical and Experimental Ophthalmology
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 11/2008

01-11-2008 | Retinal Disorders

Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration

Authors: S. Y. Cohen, D. Bremond-Gignac, G. Quentel, G. Mimoun, T. Citterio, S. Bisot-Locard, A. Beresniak

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 11/2008

Login to get access

Abstract

Aims

To assess effectiveness, cost, and cost-effectiveness of ranibizumab versus the current medical practices of treating age-related macular degeneration in France.

Methods

A simulation decision framework over 1 year compared ranibizumab versus the usual care using two effectiveness criteria: the “visual acuity improvement rate” (greater than 15 letters on the ETDRS scale) and the “rate of legal blindness avoided”. Two decision trees included various sequences of current treatments, with or without ranibizumab.

Results

Ranibizumab appeared significantly more effective than the usual care (p < 0.001), providing greater treatment success rate of visual acuity improvement (48.8% versus 33.9%). The cost of the ranibizumab strategy was higher (9,123 euros (€) over 1 year for ranibizumab versus 7,604 € for the usual care) but the average cost-effectiveness was lower – 18,721 € /success for ranibizumab versus 22,543 €/success for usual care (p < 0.001). Considering the “legal blindness avoided” success criterion, the ranibizumab strategy appeared significantly more effective (p < 0.001), providing greater treatment success rate for of legal blindness avoided than usual care (99.7% versus 93.1%) although it was more expensive (9,196 € over 1 year for ranibizumab versus 5,713 € for the usual care).

Conclusion

Ranibizumab significantly improved the rate of visual acuity improvement and reduced the rate of legal blindness. Ranibizumab appeared significantly more cost-effective than the usual treatments in terms of visual acuity improvement.
Literature
1.
Chaine G, Rohart C (2007) Epidemiology and risk factors for age-related macular degeneration. J Fr Ophtalmol 30:74CrossRef
2.
Ambati J, Ambati B, Yoo S, Ianchulev S, Adamis A (2003) Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 48:257–293PubMedCrossRef
3.
Ferris FL, Fine SL, Hyman L (1984) Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102(11):1640–1642 NovPubMedCrossRef
4.
Pina JP, Offret H, Labetoulle M (2007) Les nouveaux traitements de la DMLA. Medecine 3(10):443–445
5.
Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials – TAP report. Arch Ophthalmol 117:1329–1345
6.
Rosenfeld PJ, Heier JS, Hantsbatger G, Shams N (2006) Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 113:632CrossRef
7.
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, for the Marina Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. New Eng J Med 355:1419–1431PubMedCrossRef
8.
Bradley J, Ju M, Robinson GS (2007) Combination therapy for the treatment of ocular neovascularization. Angiogenesis 10:141–148PubMedCrossRef
9.
Rajczi A (2007) A critique of the innovation argument against a national health program. Bioethics 21(6):316–323 JulPubMedCrossRef
10.
Weinstein MC (2006) Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 24(11):1043–1053PubMedCrossRef
11.
Polsky D, Glick HA, Wilke R, Schulman K (1997) Confidence Intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ 6:243–252PubMedCrossRef
12.
Kegan B, West RW (2005) Modeling the simple epidemic with deterministic differential equations and random initial conditions. Math Biosci 195(2):179–193PubMedCrossRef
13.
Takeda AL, Colquitt JL, Clegg AJ, Jones J (2007) Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. Br J Ophthalmol 91(9):1177–1182PubMedCrossRef
14.
Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 19:361–372PubMed
15.
Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP, Hantsbarger G, Shams N (2006) Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 113(4):642.e1–4. Epub 2006 Feb 14.CrossRef
16.
Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study Group (2007) Angiographic and Optical Coherence Tomographic Results of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration. Ophthalmology 11
17.
VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupD’Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B (2006) Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 113(6):992–1001PubMedCrossRef
18.
Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D’Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD (2005) Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112(10):1747–1757PubMedCrossRef
19.
Macugen AMD Study Group (2007) Pegaptanib 1-Year Systemic Safety Results from a Safety-Pharmacokinetic Trial in Patients with Neovascular Age-Related Macular Degeneration. Ophthalmology 114(9):1702–1712CrossRef
20.
Schmidt-Erfurth U (1998) Photodynamic therapy. Minimally invasive treatment of choroidal neovascularisation. Ophthalmology 95:725–731CrossRef
21.
Kaiser PK (2006) Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open label extension. Graefe Arch Clin Exp Ophthalmol 244:1132–1142CrossRef
22.
Liggett PE, Colina J, Chaudhry NA, Tom D, Haffner G (2006) Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization. Am J Ophthalmol 142(6):1072–1074PubMedCrossRef
23.
Brown MM, Brown GC, Stein JD, Roth Z, Campanella J, Beauchamp GR (2005) Age-related macular degeneration: economic burden and value-based medicine analysis. Can J Ophthalmol 40(3):277–287PubMed
24.
Brown GC, Brown MM, Brown H, Godshalk AN (2007) Pharmacoeconomics and macular degeneration. Curr Opin Ophthalmol 18(3):206–211PubMedCrossRef
25.
Raftery J, Clegg A, Jones J, Tan SC, Lotery A (2007) Ranibizumab (lucentis) versus bevacizumab (avastin): modelling cost effectiveness. Br J Ophthalmol 91(9):1244–1246PubMedCrossRef
26.
Duru G, Auray JP, Beresniak A, Lamure M, Paine A, Nicoloyannis N (2002) Limitations of the methods used for calculating quality-adjusted life years values. Pharmacoeconomics 20(7):463–473PubMedCrossRef
27.
McGregor M, Caro JJ (2006) QALYs: are they helpful to decision-makers? Pharmacoeconomics 24(10):947–952PubMedCrossRef
28.
Bremond-Gignac D, Tixier J, Missotten T, Laroche L, Beresniak A (2002) Evaluation of the quality of life in ophthalmology. Presse Med 19;31(34):1607–1612
Metadata
Title
Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration
Authors
S. Y. Cohen
D. Bremond-Gignac
G. Quentel
G. Mimoun
T. Citterio
S. Bisot-Locard
A. Beresniak
Publication date
01-11-2008
Publisher
Springer-Verlag
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 11/2008
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-008-0890-8

Other articles of this Issue 11/2008

Graefe's Archive for Clinical and Experimental Ophthalmology 11/2008 Go to the issue

Case Report

Phenotypic non-penetrance in granular corneal dystrophy type II

Review Article

A review of in vivo animal studies in retinal prosthesis research

Letter to the Editor

Subfoveal choroidal neovascularization complicating 25-gauge trans-retinal choroidal tumor biopsy

Cataract

Depth of focus in pseudophakic eyes

Retinal Disorders

Primary vitrectomy with Densiron-68 for rhegmatogenous retinal detachment

Retinal Disorders

Prevalence and associated factors of diabetic retinopathy. The Beijing Eye Study 2006